In this article, published in MedTech Intelligence, TTP's head of Biosensing, Chris Dawson explores how manufacturers can adapt to this evolving landscape by:
- Refining device reliability and ease of use
- Leveraging automated testing and multi-physics modelling for accelerated development
- Prioritising human factors engineering to ensure seamless integration into users’ lives
With CGM devices now reaching broader markets, including OTC options and non-traditional users, the challenge lies in balancing innovation with practical solutions that drive adherence and market acceptance.
Read the article in MedTech Intelligence to uncover latest insights into how CGM technology is shaping the future of diabetes care and health management. Read the full article here
About TTP’s Biosensing Consulting Team
Specialising in the development of wearable and implantable biosensors, TTP’s Biosensor product design and development consultants deploy multidisciplinary teams, combining expert capabilities to deliver tailored solutions that meet the most demanding project requirements.
Whether navigating uncharted territories, supporting your next innovation or accelerating time to market, we solve complex challenges with engineering and scientific rigour, finding and retiring risks early to deliver high-impact, human-centred results. When your internal bandwidth is constrained, TTP is ready to deliver.
Read more about how we are accelerating continuous glucose monitoring design and development.
TTP's Biosensing team is part of our broader Medical Device Consulting business unit, consisting of 300+ engineers, scientists, and human factors specialists. For nearly four decades we've partnered with clients to develop impactful solutions, helping them achieve commercial success. See our approach to medical device design and development.
